September 30, 2022


MIRAMAR, Fla., July 15. 12, 2022 (GLOBE NEWSWIRE) — Stemtech Corporation (“Stemtech”) (OTCQB: STEK), an innovative nutraceutical company and pioneer in the field of stem cell nutrition, today announced that the company has appointed Network Marketing Izzy Matos , a Hall of Famer, becomes a founding Independent Business Partner.

“Izzy started Stemtech by implementing the original compensation plan even before the company was officially founded in 2005,” said Charles S. Arnold, Stemtech’s president and CEO. “He was responsible for developing a personal organization of over 70,000 of our over 200,000 IBPs and clients. Additionally, Izzy has traveled the world at Stemtech’s request, opening our markets and training countless distributors around the world: out of more than 55 million network marketers worldwide, Izzy is one of 150 Network Marketing Hall of Fame inductees. He was also among the highest earners in network marketing. He is 100% committed to the growth and success of Stemtech.

“Of all the accolades and accomplishments of my career, none have touched me more than being elevated to IBP Founder status,” said Izzy Matos. “Being here since the company was founded has given me the opportunity to meet and help countless people around the world achieve so many dreams. Now, in this new role, I can take those efforts to an even higher level. I am humbled and grateful to our Board of Directors and our leadership team for their faith and trust.

“I have had the privilege of knowing and working with Izzy for the past sixteen years and know that he is a true leader in the network marketing industry and will help Stemtech reach even greater heights. raised in his new role as IBP founder,” said John. W. Meyer, President and COO of Stemtech.

About Stemtech Corporationnot

Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations of its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 to 2015 , Stemtech International, Inc., has been recognized four times on the Inc. 5000 fastest growing companies listing. In 2018, the Company underwent an extensive management reorganization and continued operations under new management. Stemtech specializes in creating products and formulas protected by patents in the United States and certain international markets. The company’s patented formulas promote the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3Stemflo® MigraStem®OraStem® (Oral Health Care) and D-Fuze (EMF Blocker). Its products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit

Forward-looking statements

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements identified by words such as “believes ”, “expects”, “plans”, “estimates”, “intends”, “plans”, “target”, “projects” and similar expressions. The statements in this release are based on the current beliefs and expectations of the management of our company and are subject to significant risks and uncertainties. Actual results may differ from those set forth in forward-looking statements. Many factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, challenges inherent in new product development initiatives, the effect any competing products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is needed to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any government review of our products or practices, and other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q report filed May 16e, 2022. We undertake no obligation to update at any time any forward-looking statements or information contained in this press release or other public disclosures. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation that are tolerated by the Company must come from the Company itself and bear our name as the source.

For more information, contact:

Investor Relations: 954-715-6000, [email protected]